KDC-MN-1352 – Kodiac biolabs

Our opinion on this compoundNiche research probe

49/100

Best-characterized alpha-7 partial agonist defines class failure but retains genuine probe value

Look, encenicline is one of the most thoroughly documented failures in cognitive pharmacology, and that’s actually what makes it interesting as a research tool. The compound arrived from Bayer’s quinuclidine benzothiophene program via EnVivo Pharmaceuticals with real selectivity advantages over earlier alpha-7 candidates like GTS-21, and it hit Phase 2 with genuine signal: Cohen’s d around 0.3 to 0.5 on cognitive composites in both schizophrenia and Alzheimer populations isn’t noise. Those 2013 to 2015 readouts looked credible enough to justify two simultaneous global Phase 3 programs, which is a meaningful scientific endorsement from the field.

Then it fell apart. CIAS-1 and CIAS-2 both missed co-primary endpoints in March 2016, the Alzheimer program was on partial clinical hold after serious GI adverse events including ulceration in a small patient fraction, and Forum Pharmaceuticals closed the same year. We think the Phase 3 failure here is more informative than most, because encenicline was arguably the best-designed compound for the hypothesis: high subtype selectivity, favorable intrinsic efficacy at 60 to 70 percent of the acetylcholine maximum in heterologous expression systems, clean oral PK, and acceptable Phase 1 tolerability up to 180 milligrams. If monoselective alpha-7 partial agonism was going to move the cognitive needle in CIAS, this compound was the one to do it.

It didn’t. What that tells you is that alpha-7 alone isnt enough at the registration threshold, at least in late-stage schizophrenia cognitive impairment or Alzheimer disease. Whether the issue is downstream receptor biology in disease tissue, target expression variability, or a fundamental ceiling on the cholinergic hypothesis in these populations, the field hasn’t resolved it. Thats actually where encenicline still earns bench time: as a probe for the question, not an answer to it.

As a reference compound, it’s the most pharmacologically characterized alpha-7 partial agonist available. The published PK record from single ascending-dose Phase 1 studies is unusually detailed, the receptor pharmacology is well-defined across multiple electrophysiological preparations, and multiple chemical suppliers carry it at greater than 98 percent purity. If you’re building a combination-pharmacology study, investigating the cholinergic anti-inflammatory pathway, or asking how alpha-7 activity interacts with other receptor systems in vitro, encenicline is a cleaner tool than GTS-21 (non-selective), tropisetron (dual MoA with 5-HT3 overlay), or AVL-3288 (positive allosteric modulator, fundamentally different pharmacology).

Honestly, the score reflects a compound that sits at the intersection of deep evidence and limited promise. Novelty is low, the class is defined by clinical failure, and the translational signal ran out at Phase 3. But the evidence base is unusually rigorous, and for any lab studying alpha-7 pharmacology seriously, encenicline is the reference standard that lets you interpret everything else in the class.

Novelty: 35
Mechanism promise: 45
In-category differentiation: 60
Evidence quality: 65
Translational signal: 30
Research bench value: 68

Rationale High evidence quality from two Phase 3 programs and extensive Phase 1 PK record, but CIAS-1 and CIAS-2 both missed co-primary endpoints and the partial FDA clinical hold for GI toxicity decisively limits translational signal; residual score is driven by bench probe value as the reference alpha-7 partial agonist with unusually detailed pharmacological characterization and multi-supplier availability above 98 percent purity.

Selective alpha-7 nicotinic acetylcholine receptor partial agonist

A quinuclidine benzothiophene-2-carboxamide developed at EnVivo and advanced by Forum Pharmaceuticals through two global Phase 3 programs in schizophrenia cognitive impairment and one Phase 3 program in Alzheimer disease, terminated in March 2016 after both Phase 3 schizophrenia trials missed co-primary endpoints and following a September 2015 FDA clinical hold for severe gastrointestinal adverse events.

Abstract

Encenicline (development codes EVP-6124 and MT-4666) is a small-molecule selective partial agonist of the homopentameric alpha-7 subtype of the neuronal nicotinic acetylcholine receptor (alpha-7 nAChR), distinguished from earlier candidates in the class by its high subtype selectivity, the relatively favorable functional intrinsic activity profile (60 to 70 percent of the acetylcholine maximum response in heterologous expression systems), and a clinical development trajectory that reached two global Phase 3 programs in cognitive impairment associated with schizophrenia (CIAS-1 and CIAS-2) and one Phase 3 program in Alzheimer disease (COGNITIV-AD). The compound was originated at EnVivo Pharmaceuticals (later renamed Forum Pharmaceuticals) following the 2008 acquisition of the parent quinuclidine benzothiophene chemistry program from Bayer, and was advanced through Phase 1 first-in-human studies in 2010 to 2012, through positive Phase 2 schizophrenia and Alzheimer disease readouts in 2013 to 2015 with effect sizes of approximately Cohen’s d 0.3 to 0.5 on cognitive composite measures, and into the Phase 3 program from 2014. In September 2015 the United States Food and Drug Administration placed the Phase 3 schizophrenia trials and the Alzheimer disease trial on partial clinical hold following reports of severe gastrointestinal adverse events including nausea, vomiting, and gastrointestinal ulceration in a small fraction of patients; the hold was partially lifted in November 2015 to permit completion of the schizophrenia Phase 3 studies under modified safety protocols. In March 2016 Forum announced that both Phase 3 schizophrenia trials had missed their co-primary cognitive and functional endpoints and the program was discontinued. Forum Pharmaceuticals was wound down in 2016. Encenicline represents the most clinically developed alpha-7 nicotinic partial agonist in cognitive applications and is the principal source of the contemporary scientific assessment that monoselective alpha-7 partial agonism, despite robust preclinical pharmacology and Phase 2 cognitive signals, has not produced clinically meaningful improvement at the registration threshold in the indications studied. The compound remains commercially unavailable but is supplied as a research-grade reagent (greater than 98 percent purity) by multiple chemical suppliers and continues to serve as a reference alpha-7 nicotinic partial agonist for fundamental pharmacology research and for combination-pharmacology investigations. This monograph reviews the chemistry, synthesis, and stereochemistry of encenicline; the receptor pharmacology in molecular and electrophysiological detail; the comprehensive human pharmacokinetic record from single ascending-dose Phase 1 and bioavailability studies; the indication-by-indication clinical evidence base across schizophrenia cognitive impairment, Alzheimer disease, and selected exploratory cognitive endpoints; the reconstitution, sourcing, and stack-interaction considerations for laboratory work; the Phase 3 safety signal and its mechanistic interpretation; and a structured comparative assessment of five alpha-7 nicotinic acetylcholine receptor candidates against encenicline on five competency standards.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-1352Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Tag: KDC-MN-1352

Encenicline

Abstract

Read the full monograph